Document is current
Any future updates will be listed below
-
Authors
Griss, Johannes https://orcid.org/0000-0003-2206-9511
Gansberger, Sabina https://orcid.org/0009-0003-3204-936X
Oyarzun, Inigo https://orcid.org/0000-0003-1685-1531
Simon, Martin
Drach, Mathias C.
Nguyen, Vy
Shaw, Lisa E. https://orcid.org/0000-0003-2273-7655
Mann, Ulrike
Porkert, Stefanie
Farlik, Matthias
Weninger, Wolfgang
Dolak, Werner https://orcid.org/0000-0002-7450-4215
Aschenbrenner, Bertram https://orcid.org/0000-0003-1177-7109
Lichtenberger, Beate M. https://orcid.org/0000-0001-6882-0257
Ziegler-Santos, Shawn
Wagner, Christine
Simonitsch-Klupp, Ingrid
Wagner, Stephan N. https://orcid.org/0000-0003-4941-7029
Jonak, Constanze https://orcid.org/0000-0002-2347-436X
Brunner, Patrick M. https://orcid.org/0000-0002-3488-3345
-
Funding
Funding for this research was provided by:
Austrian Science Fund (P35937)
Austrian Science Fund (KLI 849-B)
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 23 January 2026
First Online: 4 February 2026
Competing interests
: J.G. received personal fees from AbbVie, Eli Lilly, Pfizer, Boehringer Ingelheim and Novartis. C.J. has received personal fees from Boehringer Ingelheim, LEO, Pfizer, Recordati Rare Diseases, Eli Lilly, Novartis, Takeda, Kyowa Kirin, STADA, UCB, BMS, AbbVie, Janssen, Stemline, and Almirall. C.J. is an investigator for Eli Lilly, Novartis, AbbVie, Boehringer Ingelheim, Incyte, 4SC, and Innate Pharma. W.W. has received personal fees from LEO Pharma, Pfizer, Sanofi Genzyme, Eli Lilly, Novartis, Boehringer Ingelheim, AbbVie, and Janssen. W.D. has received personal fees from Boston Scientific, Olympus, Medtronic, Norgine, MSD, Takeda and Ferring. P.M.B. has received personal fees from Almirall, Sanofi, Janssen, Amgen, LEO Pharma, AbbVie, Pfizer, Boehringer Ingelheim, GSK, Regeneron, Eli Lilly, Celgene, Arena Pharma, Novartis, UCB Pharma, Biotest and BMS. P.M.B. is an investigator for Pfizer and Abbvie.
